# Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

> **NCT07312799** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Addpharma Inc.** · enrollment: 41 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Treatment A(AD-2321)
- **DRUG:** Treatment B(AD-2322)
- **DRUG:** Treatment C(AD-2321+AD-2322)

## Key facts

- **NCT ID:** NCT07312799
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-27
- **Primary completion:** 2026-02-11
- **Final completion:** 2026-02-26
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07312799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07312799, "Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07312799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*